My IDSA Contact Us
IDSA NewsPrint-Friendly Newsletter
Forward to a Friend
Search Back Issues
Education & Training Resources Practice Guidelines Journals & Publications Policy & Advocacy Meetings About IDSA
March 2015
ID Funding Highlighted on Capitol Hill

President Obama’s budget request for Fiscal Year 2016 is now under consideration in Congress.  House and Senate spending panels are holding hearings with federal agency heads and receiving input from outside stakeholders.  

For FY 2016, President Obama proposed modest increases to agencies important to the infectious diseases community, including the Centers for Disease Control and Prevention (CDC, +1.6 percent), National Institutes of Health (NIH, +3.3 percent), and Food and Drug Administration (+5.7 percent).  The president’s request to double funding for the CDC viral hepatitis program as well as to nearly double support for antimicrobial resistance programs across the government has initially drawn positive attention on the Hill.  Most global infectious disease programs were slated for flat funding, with global tuberculosis programs again singled out for a 17 percent cut in funding.

During a March 3 hearing of NIH leaders in the House subcommittee that has oversight of much of health spending, antimicrobial resistance was mentioned as a top research priority by leaders of the subcommittee as well as by NIH Director Francis Collins, MD, and National Institute of Allergy and Infectious Diseases Director Anthony Fauci, MD, FIDSA.  Despite this agreement, many on the panel noted that sequestration poses a challenge to new spending proposals.  House and Senate leaders are separately looking at ideas to provide at least short-term relief from sequestration.  Absent an agreement, sequestration will result in a reduction to the overall federal budget for FY 2016, largely preventing agency increases.    

IDSA staff and members have been active on Capitol Hill in support of ID priorities in the budget.  IDSA is leading efforts to build support among other organizations for increased funding to address antimicrobial resistance, including coordinating a recent letter and leading groups of stakeholders in meetings with key congressional offices.  

If you have not already done so, please join the IDSA advocacy effort by taking 3 minutes to send a message to your representative and senators through the IDSA Action Center.

< Previous Article | Next Article >

Post a comment

Your name:

Your comment:

Public Comment Period for IDSA/AAN/ACR Lyme Guideline Project Plan Closes April 9
FDA Approves New Drugs, Cresemba and Avycaz
NIH Training Opportunity: Biosafety Officer in High-Containment Facility
IDSA Joins the “Choosing Wisely” Campaign to Cut Back on Unnecessary Medical Care
New Forum for Contracting and Negotiations Information Exchange
IDSA Advances Priorities in 21st Century Cures Legislation
HIVMA Receives CAEAR Coalition Partnership Award
New Statement on Criminalization of HIV and other Communicable Diseases
ID Funding Highlighted on Capitol Hill
Laboratory Developed Tests: Regulation Should Keep Pace With ID Patient Needs
IDSA Responds to NIH on Proposed Regulatory Process for Multi-Site Research Trials
NIAID Launches ClinRegs Website on International Clinical Research Regulations
Science Speaks: Coverage of CROI 2015
Education and Resources
ABIM MOC Changes
Free IDSA Hepatitis C MOC Module
IDSA to Offer Infection Control MOC Pre-Meeting Workshop at SHEA Spring Meeting
OFID is Now Indexed in PMC
Apply Now for IDSA Fellow Advancement
IDSA Begins Search for CID Editor-in-Chief
Members on the Move
New Members
From the President
Regaining Ground on Measles Eradication: The Role of the ID Specialist
Top Stories
Clinicians: Here’s How to Avoid a Payment Penalty in 2017
IDWeek Advance Registration Now Open for IDSA Members
IDSA Journal Club
IDSA | 1300 Wilson Blvd., Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200
To ensure delivery, please add '' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details.